vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and Epsilon Energy Ltd. (EPSN). Click either name above to swap in a different company.

Epsilon Energy Ltd. is the larger business by last-quarter revenue ($14.8M vs $13.5M, roughly 1.1× Assertio Holdings, Inc.). On growth, Epsilon Energy Ltd. posted the faster year-over-year revenue change (65.7% vs -57.9%). Over the past eight quarters, Epsilon Energy Ltd.'s revenue compounded faster (36.2% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Epsilon Composite is a French company created in 1987 by Stephane LULL, its current CEO. The company was founded in January 1987. Its production site is located in Gaillan, France. Stéphane Lull is the CEO.

ASRT vs EPSN — Head-to-Head

Bigger by revenue
EPSN
EPSN
1.1× larger
EPSN
$14.8M
$13.5M
ASRT
Growing faster (revenue YoY)
EPSN
EPSN
+123.7% gap
EPSN
65.7%
-57.9%
ASRT
Faster 2-yr revenue CAGR
EPSN
EPSN
Annualised
EPSN
36.2%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASRT
ASRT
EPSN
EPSN
Revenue
$13.5M
$14.8M
Net Profit
$-12.4M
Gross Margin
Operating Margin
-86.7%
-129.0%
Net Margin
-83.9%
Revenue YoY
-57.9%
65.7%
Net Profit YoY
-1535.0%
EPS (diluted)
$-4.54
$-0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
EPSN
EPSN
Q4 25
$13.5M
$14.8M
Q3 25
$49.5M
$9.0M
Q2 25
$29.2M
$11.6M
Q1 25
$26.5M
$16.2M
Q4 24
$32.2M
$8.9M
Q3 24
$29.2M
$7.3M
Q2 24
$31.1M
$7.3M
Q1 24
$32.4M
$8.0M
Net Profit
ASRT
ASRT
EPSN
EPSN
Q4 25
$-12.4M
Q3 25
$11.4M
$1.1M
Q2 25
$-16.4M
$1.6M
Q1 25
$-13.5M
$4.0M
Q4 24
$-760.8K
Q3 24
$-2.9M
$366.0K
Q2 24
$-3.7M
$815.7K
Q1 24
$-4.5M
$1.5M
Operating Margin
ASRT
ASRT
EPSN
EPSN
Q4 25
-86.7%
-129.0%
Q3 25
23.2%
6.7%
Q2 25
-27.5%
7.1%
Q1 25
-50.0%
44.3%
Q4 24
-41.9%
6.8%
Q3 24
-10.4%
3.3%
Q2 24
-11.6%
16.0%
Q1 24
-13.4%
17.6%
Net Margin
ASRT
ASRT
EPSN
EPSN
Q4 25
-83.9%
Q3 25
23.1%
11.9%
Q2 25
-56.0%
13.3%
Q1 25
-51.1%
24.8%
Q4 24
-8.5%
Q3 24
-10.0%
5.0%
Q2 24
-11.8%
11.2%
Q1 24
-13.9%
18.9%
EPS (diluted)
ASRT
ASRT
EPSN
EPSN
Q4 25
$-4.54
$-0.55
Q3 25
$0.11
$0.05
Q2 25
$-0.17
$0.07
Q1 25
$-0.14
$0.18
Q4 24
$-3.28
$-0.04
Q3 24
$-0.03
$0.02
Q2 24
$-0.04
$0.04
Q1 24
$-0.05
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
EPSN
EPSN
Cash + ST InvestmentsLiquidity on hand
$63.4M
$9.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$124.7M
Total Assets
$267.0M
$228.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
EPSN
EPSN
Q4 25
$63.4M
$9.0M
Q3 25
$93.4M
$12.8M
Q2 25
$98.2M
$9.9M
Q1 25
$87.3M
$6.9M
Q4 24
$100.1M
$6.5M
Q3 24
$88.6M
$8.3M
Q2 24
$88.4M
$8.6M
Q1 24
$80.7M
$2.3M
Total Debt
ASRT
ASRT
EPSN
EPSN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
EPSN
EPSN
Q4 25
$94.0M
$124.7M
Q3 25
$105.8M
$100.2M
Q2 25
$93.3M
$100.2M
Q1 25
$108.5M
$99.7M
Q4 24
$121.1M
$96.7M
Q3 24
$130.5M
$98.4M
Q2 24
$132.2M
$99.6M
Q1 24
$134.5M
$99.9M
Total Assets
ASRT
ASRT
EPSN
EPSN
Q4 25
$267.0M
$228.2M
Q3 25
$319.8M
$126.3M
Q2 25
$273.8M
$123.6M
Q1 25
$286.4M
$125.5M
Q4 24
$284.7M
$120.5M
Q3 24
$276.0M
$121.8M
Q2 24
$279.4M
$121.1M
Q1 24
$282.0M
$125.1M
Debt / Equity
ASRT
ASRT
EPSN
EPSN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
EPSN
EPSN
Operating Cash FlowLast quarter
$-30.0M
$-277.0K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
EPSN
EPSN
Q4 25
$-30.0M
$-277.0K
Q3 25
$-4.8M
$4.0M
Q2 25
$19.1M
$8.3M
Q1 25
$-12.5M
$8.6M
Q4 24
$11.5M
$5.0M
Q3 24
$-35.0K
$2.7M
Q2 24
$7.4M
$5.4M
Q1 24
$7.5M
$3.7M
Capex Intensity
ASRT
ASRT
EPSN
EPSN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.0%
Q2 24
Q1 24
Cash Conversion
ASRT
ASRT
EPSN
EPSN
Q4 25
Q3 25
-0.42×
3.70×
Q2 25
5.38×
Q1 25
2.14×
Q4 24
Q3 24
7.50×
Q2 24
6.60×
Q1 24
2.45×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

EPSN
EPSN

Gas Oil Ngls And Condensate$13.3M90%
Gas Gathering And Compression$1.5M10%

Related Comparisons